Title of the cohort

Cohort – Integrated multidisciplinary approach

Acronym for cohort

AMI

Name of Principal Investigator
Title Professor
First name
Last name DARTIGUES
Address of institution where award is held
Institution
Street Address
City Bordeaux
Postcode 33076
Country
  • France
Website

www.isped.u-bordeaux2.fr

Contact email
Funding source
1. The cohort includes, or expects to include, incidence of the following conditions
  • Alzheimer’s disease and other dementias
  • Parkinson’s disease
When studies on the above condition(s) are expected to become possible
  • 2011 – 2015
2a. Stated aim of the cohort

Analysis of Alzheimer disease occurrence in a rural aged population of and comparison with urban population

2b. Features distinguishing this cohort from other population cohorts

The rural origin of the selected population

3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

prevalence of dementia, prevalence of dependency, happiness, life satisfaction

3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort

The main goal is to know if a routinely pesticides using is prone to Alzheimer disease

4a. Study criteria: age range of participants at recruitment
Age in years from: 65
To (‘until death’ if applicable): until death
4b. Study criteria: inclusion criteria

over 65 years, retired people with an agricultural work before, living in a selected rural area of Gironde

4c. Study criteria: exclusion criteria

not over 65 years, not retired people with an agricultural work before, not living in a selected rural area of Gironde

5. Size of the cohort (i.e. number of participants enrolled)
  • 1,000 – 5,000 participants
6a. Measures used to characterise participants

age, gender, professional calendar (pesticides exposition), life conditions, reaction scale to life events, level of work complexity, preference scale of routinisation

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

###VALUE###

7. Study design
  • Prospective cohort
8. Cases matched by
  • Other health assessment (specify) / N/A
  • Dependency
9a. Does the study include a specialised subset of control participants
  • No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-09-2007

10a. ii) Data collection end date

01-01-2012

10a iii) Data collection for this study is
  • Data collection ongoing
  • Closed to new patients
10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – intend to apply for funding
11. Data collected
  • Only through the study
  • Through links to other records or registers (such as dental records, police records etc). Please specify
  • MSA and Agrica Files
12. System in place to enable re-contact with patients for future studies
  • Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
Yes/No % available
Data summarised in database  Yes
Database is web-based  no
Database on spreadsheet
Database is on paper
Other (specify)

 

Language used:

French

13b. Format and availability of data held as individual records
Yes/No % available
Data held as individual records  yes
Data is web-based
Data held on computer based records
Data held on cards
Other (specify)

 

Language used:

French

14a. Are data available to other groups

No

15. Data sharing policy specified as a condition of use
  • Data made publicly available after a specified time point
16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA
  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
  • Primary Samples: Stabilised samples (frozen or fixed)
  • Secondary samples: derivatives of primary samples
  • Secondary samples: plasma
  • Secondary samples: DNA
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups
  • No

Types: Population Cohorts
Member States: France
Diseases: Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders
Years: 2011
Database Categories: N/A
Database Tags: N/A

Export as PDF